GLC Biotechnology, Inc.

Solon, OH 44139

SBIR Award Summary

Total Number of Awards 9
Total Value of Awards $4.06MM
First Award Date 09/29/04
Most Recent Award Date 06/01/16

Key Personnel

Last Name Name Awards Contact
Guo Baochuan Guo 9

9 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-15-269
Budget: 06/01/16 - 01/31/17

? DESCRIPTION (provided by applicant): The objective of this SBIR Phase I project is to develop a novel sequence-specific capture (SSC) technology to quantitatively and robustly retrieve circulating miRNAs from blood, which can transform the utility of circulating miRNAs testing in diagnosis of diseases including cancer and cardiovascular dise...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-234
Budget: 05/01/14 - 01/31/15

DESCRIPTION (provided by applicant): This is the Phase I application of a SBIR project that will be devoted to develop a new fecal DNA test for CRC screening, which will utilize a new tri-marker panel discovered in our preliminary study. CRC is the second deadliest cancer in USA. The good news is that early detection along with resection is ass...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: RFA-CA-07-039
Budget: 07/01/10 - 06/30/13

DESCRIPTION (provided by applicant): This fast-track SBIR project is to develop a novel multiplexed methylation profiling assay (MMPA) technology for methylation analysis of DNA derived from clinical specimens. Specifically, we will develop the MMPA assays (one for each type of cancer) for analysis of DNA methylation in colorectal, lung, and bre...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: RFA-CA-07-039
Budget: 07/01/09 - 06/30/10

DESCRIPTION (provided by applicant): This fast-track SBIR project is to develop a novel multiplexed methylation profiling assay (MMPA) technology for methylation analysis of DNA derived from clinical specimens. Specifically, we will develop the MMPA assays (one for each type of cancer) for analysis of DNA methylation in colorectal, lung, and bre...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: RFA-CA-07-39
Budget: 09/15/08 - 05/31/09

DESCRIPTION (provided by applicant): This fast-track SBIR project is to develop a novel multiplexed methylation profiling assay (MMPA) technology for methylation analysis of DNA derived from clinical specimens. Specifically, we will develop the MMPA assays (one for each type of cancer) for analysis of DNA methylation in colorectal, lung, and bre...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/01/07 - 12/31/09

DESCRIPTION (provided by applicant): This application is to develop the PEPD technology to survey the mutation status of hundreds of DMA markers in a vast excess of wild-type DNA for cancer screening. Specifically, we will develop a fecal DMA testing assay for colorectal cancer (CRC) screening. Fecal DNA testing is emerging as a novel method for...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/26/06 - 07/31/07

DESCRIPTION (provided by applicant): This application is to develop the PEPD technology to survey the mutation status of hundreds of DMA markers in a vast excess of wild-type DNA for cancer screening. Specifically, we will develop a fecal DMA testing assay for colorectal cancer (CRC) screening. Fecal DNA testing is emerging as a novel method for...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: RFA-CA-06-01
Budget: 09/12/06 - 02/28/07

DESCRIPTION (provided by applicant): This project focuses on the development of a robust and efficient method to isolate human DNA from stool for fecal DNA screening of colorectal cancer (CRC). CRC is the second deadliest cancer in the USA and early detection is the key to eradication of this disease. Existing methods are neither sensitive nor n...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/29/04 - 10/31/05

This SBIR project is proposed to commercialize a novel method referred as PDESA for revealing patient's individual haplotypes. Our preliminary data shown that PDESA could reveal haplotypes of sequences of 134kb in length, which is about three times longer than the longest sequence haplotyped using other molecular methods. PDESA is simple, easy t...